Merck KGaA's cilengitide, a vitronectin inhibitor designed to inhibit angiogenesis, has shown promise as a treatment for recurrent glioblastoma.

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1666, 2008-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cilengitide, an integrin antagonist, has shown potential in the treatment of malignant glioma

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

The small-molecule inhibitor of survivin, YM 155, has shown promise for the treatment of solid tumours and lymphoma

By  

Inpharma, Vol. 1, Iss. 1659, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Topical becocalcidiol has shown promise in the treatment of patients with chronic plaque psoriasis

By  

Inpharma, Vol. 1, Iss. 1606, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The Vx 001 [TERT572Y] vaccine has shown promise in the treatment of advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1598, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Temozolomide in the Treatment of Recurrent Glioblastoma Multiforme

By Martikainen Janne A.  

PharmacoEconomics, Vol. 23, Iss. 8, 2005-01 ,pp. : 803-815

Adis International

Access to resources Recommend Favorite